American pharmaceutical and biotechnology company Pfizer has agreed to acquire cancer drugmaker Seagen (formerly Seattle Genetics) for $229 per share or $43 billion in cash, in a move to strengthen its position in the oncology space. With the proposed acquisition, Pfizer anticipates broadening its oncology portfolio by adding Seagen’s medicines, late-stage development programs, and antibody-drug […]
American biotechnology company Seagen (formerly Seattle Genetics) has received accelerated approval from the US Food and Drug Administration (FDA) for the company’s oral drug Tukysa (tucatinib) in combination with trastuzumab. Tukysa in combination with trastuzumab is indicated for the treatment of adult patients with RASwild-type, HER2-positive unresectable or metastatic colorectal cancer, which has advanced following […]
US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major pharma companies will develop and commercialize Seattle Genetics’ ladiratuzumab vedotin across the world. Ladiratuzumab vedotin is an investigational antibody-drug conjugate (ADC) that targets LIV-1, which is presently in phase 2 […]
Seattle Genetics, a leader in oncology biotechnology, has announced the acquisition of Cascadian Therapeutics for approximately $614 million, a strategic move to enhance its portfolio of solid tumor treatments. The acquisition, which involves Seattle Genetics paying $10 per share in cash for the California-based company, is set to significantly advance its research in cancer therapies, […]